Markets

Hyperion (HPTX) in Focus: Stock Tumbles 9.5% - Tale of the Tape

Hyperion Therapeutics, Inc. ( HPTX ) saw a big move on Friday, as the company's shares fell about 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for HPTX as the stock is now up nearly 9% in the past one-month time frame.

The commercial biopharmaceutical company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks with flat revision, and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.

HPTX currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.

Some better-ranked stocks in the same sector include Aeolus Pharmaceuticals Inc. ( AOLS ), Aerie Pharmaceuticals, Inc. ( AERI ) and Ariad Pharmaceuticals Inc. ( ARIA ). All these carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

HYPERION THERAP (HPTX): Free Stock Analysis Report

AEOLUS PHARMACT (AOLS): Get Free Report

AERIE PHARMACT (AERI): Get Free Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AOLS AERI

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More